𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin

✍ Scribed by Gwen S. Duthu


Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
439 KB
Volume
74
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Pharmacokinetics of halofantrine in the
✍ Dion R. Brocks; Jason W. Toni πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 129 KB πŸ‘ 2 views

The antimalarial drug, halofantrine, is chiral and is administered clinically as the racemate. In order to define the pharmacokinetic properties of halofantrine enantiomers in the rat, male Sprague-Dawley rats (264-311 g) were given halofantrine HCl orally (n = 5; 14 mg/kg) or intravenously (i.v.) (

Studies on the intravenous pharmacokinet
✍ S. K. Basu; P. K. Manna; B. B. Goswami πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 265 KB πŸ‘ 2 views

Pharmacokinetics in rabbits following intravenous administration and in vifro protein binding were studied for two new salts of erythromycin (erythromycin maltobionate and erythromycin fumarate). Serum erythromycin levels following intravenous injection were described by two compartment model kineti

The study of in vitro–in vivo correlatio
✍ Teerapol Srichana; Roongnapa Suedee; Det Muanpanarai; Niwan Tanmanee πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 144 KB

The pharmacokinetics and pharmacodynamics of albuterol were studied following inhalation of three different in-house dry powder formulations in healthy volunteers and in asthmatics. Albuterol in plasma was measured using liquid chromatography-mass spectrometry (LC-MS). The plasma concentration time

Assessment of ifosfamide pharmacokinetic
✍ Rashmi Chugh; Thomas Wagner; Kent A. Griffith; Jeremy M.G. Taylor; Dafydd G. Tho πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 190 KB

## Abstract ## BACKGROUND. Ifosfamide is a chemotherapeutic agent that requires cytochrome P450 3A (CYP3A) for bioactivation and metabolism. To the authors' knowledge, the correlation between dose, pharmacokinetics, CYP3A, and toxicity has not been fully evaluated. A randomized Phase II trial was